Idogen AB announces that it has successfully maximized the antigen levels in the cell therapy IDO 8 that the body should learn to recognize and tolerate. This is considered to be an important feature in order to obtain a good treatment effect. The IDO 8 treatment is aiming to create tolerance for ongoing substitution treatment with coagulation factor VIII, a vital drug for hemophilia (hemophilia A) which in many patients is inactivated as a result of undesired immune reactions. The company will shortly submit a clinical trial application to start the first study in patients. Subject to required regulatory approvals, the study is planned to start during the second quarter of 2022. A successful tech transfer and scale-up of the manufacturing process for Idogen's cell therapy has been followed by extensive work aimed at optimizing, documenting and qualifying the manufacturing process for the planned first clinical study. The company's manufacturing partner, Radboud University Medical Center (RUMC) in the Netherlands, a manufacturer of cell therapies, has now optimized and qualified the manufacturing process, achieving product properties equivalent to those generated when IDO 8 was manufactured in Idogen's own research laboratory. This has been achieved through an effective collaboration between RUMC and Idogen. Idogen's cell therapy will now be tailored for each individual patient in a GMP-certified laboratory at the company's partner Radboud University Medical Center in the Netherlands. The proprietary treatment is based on patients own cells, differentiated into dendritic cells using Idogen's unique tolerance inducers and the specific antigen that the body's immune system must learn to tolerate.